title: Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients.
abstract: OBJECTIVE
  To compare the efficacy of MTX and MTX+TNF inhibitors (TNFis) in elderly patients with RA with that in patients of younger age.
  
  
  METHODS
  Data from two large, randomized, controlled, double-blind trials in patients with early RA using adalimumab or infliximab+MTX or MTX alone were obtained and pooled. Composite disease activity indices were calculated at baseline and 1 year of treatment, and compared in groups of patients classified by quartiles of age with the highest age group comprising 61-82 years using analysis of variance or Kruskal-Wallis test.
  
  
  RESULTS
  Across all age quartiles, improvement on MTX was similar with respect to changes of composite disease activity indices, assessment of physical function and X-ray progression. Likewise, TNFi+MTX had similar effects across all age groups, but the effects of the combination were more profound than those of MTX monotherapy. Also in 10% of the patients with the highest age, primarily septuagenarians, improvement was seen to a similar degree as in the younger ones.
  
  
  CONCLUSIONS
  Responsiveness of elderly patients with RA to MTX or TNFi+MTX is similar to that observed in patients of younger age.
authors.affiliation: Department of Rheumatology/Internal Medicine III, General Hospital-Medical University of Vienna, Vienna, Austria. marcus.koeller@meduniwien.ac.at
authors.forename: Marcus D
authors.initials: MD
authors.lastname: Köller
authors.forename: Daniel
authors.initials: D
authors.lastname: Aletaha
authors.forename: Julia
authors.initials: J
authors.lastname: Funovits
authors.forename: Aileen
authors.initials: A
authors.lastname: Pangan
authors.forename: Daniel
authors.initials: D
authors.lastname: Baker
authors.forename: Josef S
authors.initials: JS
authors.lastname: Smolen
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011859:Radiography; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D008727:Methotrexate